Low-glycerin formulations for hiv treatment and prevention
AssigneeConrad
InventorDavid R. FRIEND
Life of this patent
Estimating the term…
Abstract
The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-pur: in-9-yl)-1-methyl-ethoxymethy]-phosphonic acid (tenofivir, PMPA), or a physiologically functional derivative thereof, wherein the formulations contain a low level of glycerin. Human immunodeficiency vims (HIV) infection and related diseases are a major public health problem worldwide. One approach to the problem of HIV/AIDS is to reduce the risk of transmission of HIV and thus reduce the number of individuals who become newly infected.
Claims14
A pharmaceutical formulation comprising an effective amount of a NRTI in combination with one or more of a lubricant, humectant, preservative, and thickening agent, wherein the formulation comprises less than or equal to about 5% glycerin.
Dependencies are inferred from the claim text.